Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has provided an announcement.
Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.
More about Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral small molecule therapeutics for chronic metabolic and cardiopulmonary conditions. The company uses its structure-based drug discovery platform to create a pipeline of GPCR-targeted small molecule compounds aimed at overcoming limitations of traditional biologic and peptide therapies, thereby increasing patient access worldwide.
YTD Price Performance: -23.95%
Average Trading Volume: 780,838
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.77B
See more insights into GPCR stock on TipRanks’ Stock Analysis page.
